A(nother) RAF mutation in LCH

Blood

Volumn 123, Issue 20, 2014, Pages 3063-3065

  Shannon, Kevin ^a   Hermiston, Michelle ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A RAF KINASE; B RAF KINASE; CD14 ANTIGEN; CELL SURFACE MARKER; GLYCOPROTEIN P 15095; LANGERIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; TRAMETINIB; VEMURAFENIB;

ADVANCED CANCER; AMINO ACID SUBSTITUTION; ANTIGEN PRESENTING CELL; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); ENZYME INHIBITION; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE FREQUENCY; GENETIC HETEROGENEITY; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LANGERHANS CELL; LANGERHANS CELL HISTIOCYTOSIS; LUNG ADENOCARCINOMA; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SYSTEMIC DISEASE;

ANIMALS; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS A-RAF;

EID: 84901423183     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-565481     Document Type: Review

References (10)

1. Nelson DS, Quispel W, Badalian-Very G, et al. Somatic activating ARAF mutations in Langerhand cell histiocytosis. Blood. 2014;123(20):3152-3155.
2. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAFmutant melanoma. Nature. 2010;467(7315):596- 599.
3. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
4. Badalian-Very G, Vergilio JA, Fleming M, Rollins BJ. Pathogenesis of Langerhans cell histiocytosis. Annu Rev Pathol. 2013;8:1-20.
5. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923.
6. Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669-683.
7. Flaherty KT, Robert C, Hersey P, et al; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2): 107-114.
8. Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-1586.
9. Loh ML. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br J Haematol. 2011;152(6):677-687.
10. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495-1500.